Brind.

FDA approved AVMAPKI FAKZYNJA CO-PACK treatment by Verastem Oncology.

1 report, 1 independent Updated Aug 8

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

FDA Verastem Oncology

Keep exploring

The entities involved

FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56
Verastem Oncology
Pharmaceutical company in Masachussets, United States

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 8Business WireVerastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks o